Clinical Trial Update: Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of Gardasil 9 in Japanese boys and girls has completed, with results posted on 2025-05-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2025-05-30